The team, led by neurosurgeon Todd Mainprize, MD, and physicist Kullervo Hynynen, PhD, infused the chemotherapy agent doxorubicin, along with tiny gas-filled bubbles, into the bloodstream of a patient with a brain tumor. They then applied focused ultrasound to areas in the tumor and surrounding brain, causing the bubbles to vibrate, loosening the tight junctions of the cells comprising the blood-brain barrier and allowing high concentrations of the chemotherapy to enter targeted tissues.
鈥淭he blood-brain barrier has been a persistent impediment to delivering valuable therapies to treat tumors,鈥� said Dr. Mainprize. 鈥淲e are encouraged that we were able to open this barrier to deliver chemotherapy directly into the brain, and we look forward to more opportunities to apply this revolutionary approach.鈥�
This patient treatment is part of a of up to 10 patients to establish the feasibility, safety and preliminary efficacy of focused ultrasound to temporarily open the blood-brain barrier to deliver chemotherapy to brain tumors. The is currently funding this trial through their Cornelia Flagg Keller Memorial Fund for Brain Research.
鈥淏reaching this barrier opens up a new frontier in treating brain disorders,鈥� said Neal Kassell, MD, Chairman of the Focused Ultrasound Foundation. 鈥淲e are encouraged by the momentum building for the use of focused ultrasound to non-invasively deliver therapies for a number of brain disorders.鈥�
Opening the blood-brain barrier in a localized region to deliver chemotherapy to a tumor is a predicate for utilizing focused ultrasound for the delivery of other drugs, DNA-loaded nanoparticles, viral vectors, and antibodies to the brain to treat a range of neurological conditions, including various types of brain tumors, Parkinson鈥檚, Alzheimer鈥檚 and some psychiatric diseases.
The procedure was conducted using Insightec鈥檚 ExAblate Neuro system. 鈥淭his first patient treatment is a technological breakthrough that may lead to many clinical applications,鈥� said Eyal Zadicario, Vice President for R&D and Director of Neuro Programs, Insightec.
While the current trial is a first-in-human achievement, Dr. Kullervo Hynynen, senior scientist at the Sunnybrook Research Institute, has been performing similar pre-clinical studies for about a decade. His research has shown that the combination of focused ultrasound and microbubbles may not only enable drug delivery, but might also stimulate the brain鈥檚 natural responses to fight disease. For example, the temporary opening of the blood-brain barrier appears to facilitate the brain鈥檚 clearance of a key pathologic protein related to Alzheimer鈥檚 and improves cognitive function.
A by Gerhard Leinenga and J眉rgen G枚tz from the Queensland Brain Institute in Australia further corroborated Hynynen鈥檚 research, demonstrating opening the blood-brain barrier with focused ultrasound reduced brain plaques and improved memory in a mouse model of Alzheimer鈥檚 disease.
Based on these two pre-clinical studies, a pilot clinical trial using focused ultrasound to treat Alzheimer鈥檚 is being organized.
VIRTUAL PRESS CONFERENCE
Tuesday, November 10, 2015 at 1:00 p.m. ET
Who:Todd Mainprize, MD, Neurosurgeon, Sunnybrook Health Sciences CentreNathan McDannold, PhD, Associate Professor of Radiology, Brigham and Women鈥檚 Hospital Jessica Foley, PhD, Chief Scientific Officer, Focused Ultrasound Foundation
Room opens 12:45 PM Nov 10 for technical helpNeed Assistance? 434-296-9417 (麻豆传媒 Support)
About The Blood-Brain BarrierThe blood-brain barrier (BBB) is a protective layer of tightly joined cells that lines the blood vessels of the brain and keeps harmful substances, such as toxins and infectious agents, from entering the surrounding tissue. Unfortunately, this barrier also prevents certain drugs from reaching their targets within the brain in adequate concentrations. Safely and temporarily opening the barrier in a well-defined area to deliver drugs at therapeutic levels is a long-sought goal for treatment of a wide variety of neurological conditions including brain tumors, Alzheimer's disease, Parkinson's disease and epilepsy.
Currently, there are limited options to circumvent the blood-brain barrier and deliver drugs. Drugs can be directly injected into the brain, with the risk of hemorrhage, infection or damage to normal brain tissue from the needle or catheter. The pharmacological agent mannitol has been used to disrupt the barrier when injected into the blood supply, but this approach is uncontrolled and non-selective and can further be associated with significant effects on blood pressure and the body鈥檚 fluid balance.
About Focused UltrasoundFocused ultrasound uses ultrasonic energy guided by magnetic resonance or ultrasound imaging to treat tissue deep in the body without incisions or radiation. Multiple intersecting beams of ultrasound are directed and concentrated on a target, much like a magnifying glass can focus multiple beams of light on a single point. Where each individual beam passes through the tissue, there is no effect. But, at the focal point, the convergence of the multiple beams of focused ultrasound energy results in many important biological effects depending on the nature of the tissue and the ultrasound parameters.
There are currently 18 known of focused ultrasound, including several methods of drug delivery, such as disrupting the blood-brain barrier.
There are focused ultrasound systems currently approved in the U.S. to treat uterine fibroids, ablate prostate tissue and alleviate pain from bone metastases. There are a growing number of in various stages of research and development around the world, including Parkinson鈥檚 disease, essential tremor, breast cancer, liver cancer and hypertension.
About the Focused Ultrasound FoundationThe Focused Ultrasound Foundation was created to improve the lives of millions of people worldwide by accelerating the development of focused ultrasound. Since its establishment in 2006, the Foundation has become the largest non-governmental source of funding for focused ultrasound research. More information can be found at .
RSS